Physician profile
William Lacorte
NPI 1619065497
$1,317.64
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $121 · 2021: $255 · 2022: $186 · 2023: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $176.63 | 2019-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $132.50 | 2019-2022 | |
| Urovant Sciences INC | $130.13 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $129.24 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.78 | 2019 | |
| Cardinal Health 200 LLC | $114.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $108.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.62 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $56.38 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.55 | 2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $29.55 | 2023 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $25.09 | 2023 | |
| Allergan, INC. | $24.94 | 2019-2020 | |
| Smith+Nephew, INC. | $24.47 | 2020-2022 | |
| Biogen, INC. | $18.50 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.82 | 2019 | |
| Nabriva Therapeutics, Plc | $15.49 | 2020 | |
| Almatica Pharma LLC | $14.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.59 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.49 | 2022 | |
| Kci USA, INC. | $14.40 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lacorte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.